EXPLORING THE MECHANISMS OF SUPERIOR COGNITIVE PERFORMANCE IN SCHIZOPHRENIA
EXPLORING THE MECHANISMS OF SUPERIOR COGNITIVE PERFORMANCE IN SCHIZOPHRENIA
批准号:
7718181
负责人:
ABRAHAM REICHENBERG
金额:
$0.34万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2009-02-28
关键词:
AnteriorBrainBrain regionCharacteristicsClinicalCognitiveComputer Retrieval of Information on Scientific Projects DatabaseEpidemiologic StudiesExhibitsFunctional disorderFundingGrantImpaired cognitionImpairmentIndividualInstitutionIntelligenceLeftNeurophysiology - biologic functionNeuropsychological TestsNormal RangePatientsPerformancePopulationPsychopathologyResearchResearch PersonnelResourcesSchizophreniaScoreShort-Term MemorySourceSymptomsUnited States National Institutes of Healthexecutive functionfunctional disabilityneuropsychologicalprocessing speed
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Numerous clinical as well as epidemiological studies have documented severe intellectual deficits in schizophrenia patients. The intellectual deficits have been associated with resulting functional impairments. While it is clear that overall, low intellectual ability is a characteristic of a majority of schizophrenia patients, about 20%-30% have no apparent cognitive impairments. About 13% of patients have IQ scores of 110 or higher, suggesting that a respectable proportion of patients maintain superior intellectual abilities. Although it has been suggested that schizophrenia patients with intellectual ability 'within normal range' still exhibit impairments in executive functions and processing speed compared with normal individuals, the performance of patients with superior intelligence (IQ>115) on specific neuropsychological tests remains unknown. Furthermore, brain function has never been directly studied in this population. The study of schizophrenia patients with superior intellectual capacity has the potential of identifying unaffected, or protective, neural functions. It may also help elucidate the relationship between psychopathology and cognitive impairment, by clarifying the pathophysiology underlying schizophrenic symptoms.
Hypotheses:
A. Schizophrenia patients with superior intelligence (IQ>115) will present neuropsychological performance and symptom profiles different from schizophrenia patients with normal or low IQ(<115), and controls.
B. Similar to schizophrenia patients with normal or low IQ(<115), schizophrenia patients with superior intelligence (IQ>115) will present a characteristic reduced DLPFC activation during a working memory task compared to controls. Other brains regions (in particular in anterior cingulate and left frontal pole) will show increased activation compared to controls and schizophrenia patients with normal or low IQ.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The impact of social isolation on aging health in schizophrenia
-
批准号:10680522
-
项目类别:
-
资助金额:$64.44万
-
财政年份:2022
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
The impact of social isolation on aging health in schizophrenia
-
批准号:10522303
-
项目类别:
-
资助金额:$76.41万
-
财政年份:2022
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Autism and Prenatal Endocrine Disruptors (A-PED)
-
批准号:10251532
-
项目类别:
-
资助金额:$7.4万
-
财政年份:2021
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Autism Risk and Maternal Cardiometabolic Health (ARCH) study
-
批准号:10674627
-
项目类别:
-
资助金额:$65.63万
-
财政年份:2019
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Autism Risk and Maternal Cardiometabolic Health (ARCH) study
-
批准号:10443600
-
项目类别:
-
资助金额:$66.03万
-
财政年份:2019
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Autism Risk and Maternal Cardiometabolic Health (ARCH) study
-
批准号:10178066
-
项目类别:
-
资助金额:$65.17万
-
财政年份:2019
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Autism and Prenatal Endocrine Disruptors (A-PED)
-
批准号:9349499
-
项目类别:
-
资助金额:$60.63万
-
财政年份:2016
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Autism and Prenatal Endocrine Disruptors (A-PED)
-
批准号:9133065
-
项目类别:
-
资助金额:$63.08万
-
财政年份:2016
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Autism and Prenatal Endocrine Disruptors (A-PED)
-
批准号:10006730
-
项目类别:
-
资助金额:$57.99万
-
财政年份:2016
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Multigenerational FamIlial and Environmental Risk for Autism (MINERvA) Network
-
批准号:9121391
-
项目类别:
-
资助金额:$98.99万
-
财政年份:2012
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Multigenerational FamIlial and Environmental Risk for Autism (MINERvA) Network
-
批准号:8537788
-
项目类别:
-
资助金额:$94.84万
-
财政年份:2012
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
Multigenerational FamIlial and Environmental Risk for Autism (MINERvA) Network
-
批准号:8386420
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2012
-
负责人:ABRAHAM REICHENBERG
-
依托单位:
国内基金
海外基金
Sitagliptin通过microbiota-gut-brain轴在2型糖尿病致阿尔茨海默样变中的脑保护作用机制
-
批准号:81801389
-
项目类别:青年科学基金项目
-
资助金额:21.0万元
-
批准年份:2018
-
负责人:田茗源
-
依托单位:
平扫描数据导引的超低剂量Brain-PCT成像新方法研究
-
批准号:81101046
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:黄静
-
依托单位: